Chiesi Acquires KalVista for $1.9 Billion in Rare Disease Push

Italy's Chiesi Group has finalized a deal to acquire KalVista Pharmaceuticals, a Nasdaq-listed biotech firm, for approximately $1.9 billion (€1.62 billion), marking the Parma-based pharmaceutical company's largest acquisition ever by value. The transaction, announced on April 29, positions Chiesi to claim a strategic foothold in the U.S. rare disease market through a first-of-its-kind oral therapy for a life-threatening genetic disorder.

Why This Matters

• Expansion of Italian pharma footprint: Chiesi's U.S. commercial infrastructure gains immediate scale, advancing the company toward its €6 billion revenue target by 2030.

• New treatment option: The acquisition delivers Ekterly (sebetralstat), the only FDA-approved oral, on-demand therapy for hereditary angioedema (HAE), a condition affecting thousands.

• Premium deal terms: Chiesi offered $27 per share in cash, representing a 36% premium over KalVista's recent trading average, signaling aggressive confidence in the asset.

• Timeline: The deal is expected to close by September 2026, pending regulatory clearance and shareholder approval.

What Chiesi Is Buying

The centerpiece of the acquisition is Ekterly, a plasma kallikrein inhibitor approved by the U.S. Food and Drug Administration in July 2025 for patients aged 12 and older. HAE is a rare genetic disorder that triggers sudden, unpredictable swelling attacks—often in the face, throat, limbs, or abdomen—that can be painful and, in severe cases involving the airway, fatal. Until Ekterly's approval, most on-demand treatments required injection or infusion, creating logistical and comfort barriers for patients.

Ekterly offers a pill-based alternative patients can carry and take as soon as symptoms appear, addressing what Chiesi executives describe as a "significant unmet clinical need." Following its U.S. commercial launch in July 2025, the drug generated $49 million in sales by year-end and had reached nearly 20% of the U.S. HAE patient population by February 2026, according to KalVista's disclosures.

Clinical trials are underway to extend Ekterly's label to children between 2 and 11 years old, with a submission to the FDA anticipated later this year and potential approval in 2027.

Strategic Fit for Chiesi Global Rare Diseases

The deal reinforces Chiesi's aggressive push into rare immunology, an area the company has prioritized through both organic R&D and external acquisitions. The company's Global Rare Diseases unit, led by Giacomo Chiesi, has been the engine behind this strategy, focusing on ultra-rare and orphan conditions where treatment options remain limited.

Chiesi's rare disease portfolio already includes Filsuvez, acquired through the €1 billion takeover of Amryt Pharma in 2023, and Elfabrio, a gene therapy. The addition of Ekterly significantly bolsters the rare immunology pillar, complementing therapies targeting metabolic and pulmonary rare diseases.

For context, Chiesi reported €3.6 billion in global revenue in 2025, with the U.S. market growing 23.5% year-over-year, driven largely by the rare diseases division. The KalVista acquisition is projected to contribute materially to the company's ambition to hit €6 billion by 2030, a target that hinges on expanding its specialty portfolio and deepening its U.S. commercial presence.

Deal Structure and Financial Terms

Both boards have approved the transaction, which takes the form of a tender offer. Chiesi will pay $27 per share in cash to KalVista shareholders, valuing the company at roughly $1.9 billion on a fully diluted basis. The premium represents a 36% markup over KalVista's 30-day volume-weighted average price as of April 28, reflecting not only the drug's demonstrated early commercial traction but also its pipeline potential and the strategic value of immediate U.S. market access.

The deal is expected to close in the third quarter of 2026, subject to customary closing conditions including antitrust clearance and approval by KalVista shareholders. No financing contingencies have been disclosed, suggesting Chiesi is proceeding with committed capital, likely a mix of internal resources and debt facilities.

Impact on Expats & Investors

For Italian nationals living abroad, particularly those with ties to the Emilia-Romagna region where Chiesi is headquartered, the deal underscores the global competitiveness of Italian-origin pharma companies in high-value biotech acquisitions. Chiesi remains a family-owned enterprise, a structure that is increasingly rare among pharmaceutical majors and which affords the company long-term strategic flexibility uncommon among publicly traded peers.

For investors and professionals in the life sciences sector, the acquisition signals that Italian biopharma is willing to deploy substantial capital to secure novel assets with global commercial potential. Chiesi's willingness to pay a substantial premium for a recently approved, commercially de-risked asset reflects a broader industry trend: in-licensing or acquiring late-stage or marketed rare disease therapies rather than relying solely on internal pipelines.

The deal also has employment implications. KalVista, based in Massachusetts, employs a specialized commercial and clinical team in the U.S. Chiesi has not disclosed integration plans, but typically such acquisitions result in the retention of commercial personnel to maintain continuity with prescribers and patient advocacy groups.

Broader Context: Chiesi's M&A Appetite

This acquisition follows a pattern of targeted, high-conviction deals by Chiesi over the past several years. The €1 billion Amryt acquisition in 2023 brought Filsuvez, a treatment for epidermolysis bullosa, into the fold. In October 2025, Chiesi announced a partnership with Arbor Biotechnologies to explore gene-editing programs, marking its entry into genetic medicine.

The company has also pursued diagnostic innovation, partnering with Samay in October 2025 to develop tools for early detection of small airway diseases. These moves collectively suggest Chiesi is positioning itself as a vertically integrated rare disease player, controlling not only therapeutics but also diagnostic and precision medicine capabilities.

What Comes Next

Assuming the deal closes as planned, Chiesi will integrate KalVista's U.S. commercial operations and likely expand Ekterly's reach beyond the American market, leveraging its European and global infrastructure. The company has indicated it plans to pursue label expansions and additional indications, including the pediatric population and potentially prophylactic (preventive) use in HAE.

For patients, the acquisition is likely to mean continued investment in Ekterly's availability and affordability, though pricing and reimbursement dynamics in Europe—where healthcare systems negotiate drug costs more aggressively—remain to be seen.

For Chiesi, the transaction represents a calculated bet on rare immunology as a high-margin, fast-growing segment. With the U.S. as the world's largest pharmaceutical market and rare disease drugs commanding premium pricing, the deal aligns with the company's long-term vision to become a top-tier global player in orphan therapeutics.

The transaction awaits regulatory blessing and shareholder votes, but barring unforeseen complications, Chiesi's footprint in the U.S. rare disease landscape will be significantly larger by autumn.